BS_1EN5V3XW
high-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- high-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- high-grade glioma
- overall_survival_months
- 23.915900131406044
- age_years
- 15.764
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.490
- E2F_TARGETS+0.483
- G2M_CHECKPOINT+0.464
- MITOTIC_SPINDLE+0.379
- MYC_TARGETS_V1+0.372
- DNA_REPAIR+0.361
- NOTCH_SIGNALING+0.258
- MYC_TARGETS_V2+0.234
- HEDGEHOG_SIGNALING+0.211
- OXIDATIVE_PHOSPHORYLATION+0.104
Top 10 suppressed
- INFLAMMATORY_RESPONSE-0.441
- ALLOGRAFT_REJECTION-0.426
- IL2_STAT5_SIGNALING-0.407
- IL6_JAK_STAT3_SIGNALING-0.401
- APICAL_SURFACE-0.374
- KRAS_SIGNALING_UP-0.350
- COMPLEMENT-0.335
- INTERFERON_GAMMA_RESPONSE-0.311
- TNFA_SIGNALING_VIA_NFKB-0.303
- COAGULATION-0.281
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_5P1TN10Z | Embryonal tumors | — | 0.912 |
| 2 | ERR2598206 | fetal | fetal | 0.911 |
| 3 | ERR2598195 | fetal | fetal | 0.907 |
| 4 | ERR2598238 | fetal | fetal | 0.906 |
| 5 | TCGA-33-4587-01A-11R-2125-07 | — | cohortMD1 | 0.891 |
| 6 | 4938761D-0762-4984-A399-BC036D6D2140 | — | — | 0.891 |
| 7 | SRR934765 | — | — | 0.890 |
| 8 | TCGA-O2-A5IB-01A-11R-A27Q-07 | — | cohortMD1 | 0.887 |
| 9 | ERR2598226 | fetal | fetal | 0.885 |
| 10 | ERR2598235 | fetal | fetal | 0.884 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.490 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.483 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.464 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.379 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.372 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.361 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.258 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.234 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.211 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.104 | Remibrutinib | — uncovered |
| PEROXISOME | 0.091 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.046 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.039 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.006 | Idelalisib | — uncovered |